Breaking News, Collaborations & Alliances

Precision, MaxCyte Enter Clinical Agreement

Allows Precision to use MaxCyte's Flow Electroporation® technologies to robustly deliver ARCUS genome-editing technology

Precision BioSciences (Precision) and MaxCyte have entered into a non-exclusive, clinical and commercial license agreement that will allow Precision to use MaxCyte’s Flow Electroporation® technologies to robustly deliver Precision’s proprietary ARCUS genome-editing technology for use in next-generation gene edited allogeneic T-cell immunotherapies designed to treat a broad range of cancers. David Thomson, chief development officer of Precision, said, “Precision’s thera...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters